Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06242067 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Second-line Treatment of Metastatic Colorectal Cancer

Study acronym: BEV-TASIRI
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated February 5, 2024 (before its estimated December 2024 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
The goal of this multicenter, single-arm, observational cohort study is to investigate the efficacy and safety of irinotecan in combination with trifluridine-tipiracil and bevacizumab in colorectal cancer with prior oxaliplatin and fluoropyrimidine-based chemotherapy (including 5-FU/capecitabine/S-1) exposure in the metastatic setting or within 12 months of recurrence.
Trial Details
NCT Number NCT06242067
Lead Sponsor Qilu Hospital of Shandong University
Collaborators: The Affiliated Hospital of Qingdao University, Shandong Provincial Hospital, Qianfoshan Hospital, Binzhou People's Hospital, Binzhou Medical University, Yantai Yuhuangding Hospital, Linyi Tumour Hospital
Conditions
(from sponsor)		 Metastatic Colorectal Cancer
Related terms Colorectal Neoplasms
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov